Accelerating Therapeutic Antibody Discovery: Phage Display & B-Cell Sorting with Biotinylated NiV Proteins

Screening Technology Overview: Phage Display vs. Single B-Cell Sequencing

Nipah virus (NiV), designated as a priority pathogen by the World Health Organization (WHO), demands rapid discovery of therapeutic antibodies to address potential outbreak threats. The two dominant antibody screening technologies—phage display and single B-cell sequencing—each offer distinct advantages in NiV antibody development.

Table 1. Comparison of Phage Display and Single B-Cell Sequencing Technologies

Feature	Phage Display	Single B-Cell Sequencing
Antibody Source	Synthetic/naïve libraries (10⁹-10¹¹ diversity)	B cells from immunized animals/convalescent patients
Chain Pairing	Random pairing in vitro	Preserves natural heavy-light chain pairing
Affinity Maturation	In vitro simulation	Retains in vivo affinity maturation imprints
Screening Timeline	2-4 weeks	3-5 weeks (including immunization)
Humanization Requirements	Requires subsequent humanization	Direct access to fully human or humanized antibodies
Epitope Coverage	Biased toward high-affinity epitopes	Covers full spectrum of natural immune response epitopes
Typical Applications	Rapid lead antibody generation (e.g., m102.4)	Discovery of broadly neutralizing antibodies

In NiV research, phage display has successfully identified the human monoclonal antibody m102.4 targeting the G protein, which demonstrates potent neutralizing activity against both NiV and Hendra virus. Meanwhile, single B-cell sorting technology utilizes multicolor flow cytometry to isolate broadly neutralizing antibodies against the F protein from immunized mice, revealing novel vulnerable epitopes on the prefusion F protein.

The Critical Role of Antigen Format: Advantages of Site-Specific Biotinylation (Avi-tag)

During antibody screening, the method of antigen labeling directly impacts epitope integrity and screening efficiency. Compared to traditional chemical biotinylation (e.g., NHS-ester labeling), enzymatic site-specific biotinylation (Avi-tag technology) demonstrates significant advantages.

Preservation of Native Epitope Structure

The Avi-tag is a 15-amino-acid peptide (GLNDIFEAQKIEWHE) that can be specifically recognized by BirA enzyme both in vivo and in vitro, attaching biotin to a lysine residue. This site-specific labeling approach avoids random modification of surface lysines by chemical labeling, maximally preserving the integrity of conformation-sensitive epitopes.

Reduced Steric Hindrance and Optimized Orientation

Fig 1. Schematic Comparison of Avi-tag Site-Specific Biotinylation vs. Chemical Labeling Antigen Orientation

By strategically placing the Avi-tag at the C-terminus or a flexible loop region, antigen molecules present in a uniform orientation away from the solid-phase surface after Streptavidin magnetic bead or fluorophore labeling, significantly reducing steric hindrance and improving antibody accessibility.

Labeling Efficiency and Batch Consistency

Enzymatic biotinylation achieves near 100% labeling efficiency, and unlabeled proteins can be easily removed through simple Streptactin or Streptavidin affinity chromatography. In contrast, the heterogeneity of chemical labeling may lead to false positives or missed detection during screening.

Optimized Experimental Workflows

Streptavidin Magnetic Bead Panning Strategy (Phage Display)

The phage display panning workflow utilizing biotinylated NiV proteins is as follows:

Table 2. Optimization of Phage Display Panning Parameters

Step	Key Parameters	Optimization Recommendations
Antigen Immobilization	Biotinylated NiV-G/F protein concentration	50-200 nM (first round), progressively decreasing
Bead Selection	M-280 Streptavidin Dynabeads	Pre-blocking: 1% BSA/PBS, room temperature 1h
Library Pre-treatment	Negative selection (Depletion)	Pre-adsorption against irrelevant antigen beads, BSA, IgG
Binding Conditions	Time/Temperature	Room temperature 1h, gentle rotation
Wash Stringency	PBST concentration (Tween-20)	0.05%→0.1%→0.5% progressive increase
Elution Method	Acidic elution (0.1 M Glycine, pH 2.7)	Immediate neutralization with 1 M Tris-HCl (pH 8.0)
Recovery Amplification	ER2738 host bacteria	OD₆₀₀=0.5, infection ratio 1:10

Key Optimization Points:

• Soluble antigen competitive panning: Introducing soluble biotinylated antigen in later rounds for competitive elution can specifically enrich high-affinity clones
• Automation platforms: Implementing KingFisher FLEX automated magnetic bead processing systems improves reproducibility and throughput
• Cross-reactivity screening: Alternating panning with biotinylated NiV and Hendra virus antigens enriches for broadly reactive antibodies

Flow Cytometry (FACS) Using Tetramer Antigens for Enrichment of Specific B Cells

Single B-cell sorting technology utilizes fluorescently labeled antigen tetramers to enrich antigen-specific B cells from immunized animal or patient samples.

Fig 2. Workflow for NiV-Specific B-Cell Sorting Based on Tetramer Antigens

Experimental Protocol Highlights:

Table 3. FACS Sorting Parameters for NiV-Specific B Cells

Step	Reagents/Parameters	Detailed Description
Sample Preparation	Spleen cell suspension	Density 1×10⁷ cells/mL, 500 μL system
Viability Staining	7-AAD (2%)	Added 5 minutes before sorting, excludes dead cells
Fc Blocking	TruStain FcX	Blocks non-specific Fc receptor binding
B Cell Identification	CD19-FITC, IgG-BV510	Memory B cell phenotype: CD19⁺IgG⁺IgM⁻IgD⁻
Antigen Probes	APC-NiV-G, PE-NiV-F	Biotinylated antigen pre-mixed with Streptavidin-fluorophores to form tetramers
Double-Positive Gating	PE⁺APC⁺	Excludes single-positive non-specific binding cells
Sorting Settings	100 μm nozzle, 20 psi	Event rate ≤2000/s, ensures cell viability
Single-Cell Collection	96-well PCR plates	5 μL lysis buffer per well, stored at -80°C

Tetramer Preparation Key: Biotinylated NiV protein is mixed with Streptavidin-fluorophores at a 4:1 molar ratio to form tetramer complexes. Tetramerization significantly enhances affinity for B-cell surface BCRs (avidity effect), effectively enriching low-frequency antigen-specific B cells (typically <0.1% of total B cells).

Case Study: Broadly Neutralizing Antibody Screening Strategy Targeting the G Protein Head Domain

Background and Design

The NiV G protein (receptor-binding protein, RBP) recognizes host cell receptors ephrin-B2/B3 and serves as the primary target for neutralizing antibodies. While the G protein head domain contains the receptor-binding site, surface hypervariable regions may enable immune evasion. This case study demonstrates how biotinylated G proteins can be utilized to screen for broadly neutralizing antibodies targeting conserved cryptic epitopes.

Screening Strategy

Phase One: Phage Display Primary Screening

• Perform 4 rounds of panning on a fully human phage display library (10¹² diversity) using biotinylated NiV-G-Head-Avi-tag protein
• Strategy: First round uses high antigen concentration (200 nM) to capture diverse clones, with subsequent rounds decreasing to 10 nM and extending wash times (1 min→5 min→10 min)
• Rounds 3-4 introduce Hendra virus G protein cross-panning to enrich for cross-reactive clones

Phase Two: Single B-Cell Sorting Validation

• Immunize mice with prefusion-stabilized NiV G protein (containing Avi-tag) combined with CpG adjuvant
• Sort cross-reactive B cells using PE-NiV-G + APC-Hendra-G dual tetramer probes
• Collect double-positive cells via index sorting into 96-well plates, perform single-cell RT-PCR amplification of VH/VL genes

Results and Characterization

Through this strategy, the fully human single-domain antibody (VHH) n425 was successfully isolated. This antibody targets a highly conserved cryptic epitope at the G protein dimer interface, inhibiting F protein activation and membrane fusion by disrupting G protein tetramerization.

Table 4. Comparison of Candidate Antibody Functional Properties

Antibody	Target	Epitope Location	Neutralization Mechanism	Blood-Brain Barrier Penetration	In Vivo Protection Efficacy
m102.4	G protein	Head domain surface	Blocks receptor binding	Moderate	Effective (delayed administration)
n425	G protein	Dimer interface (cryptic epitope)	Disrupts G tetramerization, inhibits F activation	Excellent	Superior to m102.4
1F3	F protein	Domain 3 apex	Inhibits conformational changes	Under evaluation	Effective

Structural Biology Validation: Cryo-EM structural analysis of the n425-NiV G complex (resolution ≤3.0 Å) confirmed that this antibody binding site is 100% conserved between NiV and Hendra viruses, and located distant from known antigenic drift hotspots.

Conclusions and Future Perspectives

Utilizing Avi-tag site-specific biotinylated NiV proteins combined with phage display and single B-cell sorting technologies enables efficient discovery of therapeutic antibodies targeting conserved vulnerable epitopes. Key success factors include:

1. Antigen Design: Employing prefusion-stabilized conformations to preserve neutralization-sensitive epitopes
2. Labeling Strategy: Enzymatic biotinylation ensures epitope integrity and uniform orientation
3. Screening Logic: Cross-reactive panning/sorting strategies enrich for broadly neutralizing antibodies
4. Functional Screening: Early integration of pseudovirus neutralization assays to ensure biological relevance

Future directions include the development of bispecific antibodies (simultaneously targeting G and F proteins) and nanoparticle display of biotinylated antigens to further enhance immunogenicity and breadth of cross-protection.

References

1. Wang Z, et al. Architecture and antigenicity of the Nipah virus attachment glycoprotein. Science. 2022;375(6583):1373-1378.
2. Dang HV, et al. Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein. Nat Commun. 2023;14:1575.
3. Loomis RJ, et al. Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Front Immunol. 2020;11:842.
4. Avanzato VA, et al. A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. Proc Natl Acad Sci USA. 2019;116(50):25057-25067.
5. Dang HV, et al. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Nat Struct Mol Biol. 2019;26(10):980-987.
6. Dang HV, et al. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nat Struct Mol Biol. 2021;28(4):426-434.
7. Mire CE, et al. A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection. J Infect Dis. 2020;221(Suppl 4):S471-S479.
8. Tamin A, et al. Functional properties of the fusion and attachment glycoproteins of Nipah virus. Virology. 2002;296(2):190-200.
9. Wang L, et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect. 2001;3(4):279-287.
10. Chattopadhyay A, Rose JK. Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach. J Virol. 2011;85(5):2004-2011.